Ipsogen, a company that markets molecular diagnostics assays for leukaemia, has launched MapQuant DxT Genomic Grade. The new assay is a molecular diagnostic test for breast tumour grade, which is an indicator of tumour proliferation, metastasis risk and response to chemotherapy.
UK NEQAS IMPROVES PATIENT CARE
We aim to improve patient care through monitoring the quality of tests and their reporting, in an independent manner and on a not-for-profit basis.
We are here to help ensure optimal quality in testing for the benefit of patients.
We believe that the result of tests should be:
ACV, Vienna, Austria
6 -10 September, 2025
The International Convention Centre (ICC), Birmingham
22-25 September, 2025
The Catalyst, Newcastle
3 October
Manchester Conference Centre
8 October
Online
11-13 November, 2025
